Thinking their convertibles will hold this back for a bit. Getting ready to give away even more...
Low of .81 yesterday. Dodged the drop on this but still keeping it on my list.
Hmmm… since you are here, I believe that something may come out of it
High 1.53. $ENSC
Wasn't even on my list. Nice Monk!
Bought TPST last night at 48 cents
ENSC is nothing
Sooner later if some big news hits the wires, there is going to be a bloodbath of shorts lying in a ditch on the side of the road, covered in so much of each other's blood, that it will be seen from space as a big red dot.
There is some very corrupted hedge funds involved with the manipulation trading activity in this stock, like the example in the warrants every time there is a big buyer of them like today at $0.015 some little moron sells like one warrant back on the bid, like a little spiteful 12 year old kid, it's gotten to the point that a group of investors have contacted the SEC to request an open investigation for any noticeable stock manipulation, and were told they will monitor it in the future for any that violations.
rediculous float. https://finviz.com/quote.ashx?t=ENSC&p=d
Anything good happens here and what's left of the shorts will be toast. Offering was in the 3.80's.
Presentation coming up in Las Vegas.
Roll the dice baby!!
ENSC: Indeed, Sir --- and, up a little in the A.H. right now; as @VINE goes down the proverbial toilet in the A.H. (NOT to disparage those who scored huge today over on THAT one.)
nsysce Biosciences Announces Successful Completion of Ground-Breaking Study on Overdose Protection
~ Represents Major Milestone Towards Launch of PF614-MPAR ~
~ PF614-MPAR on Track to be the First Drug to Protect Against Overdose ~
SAN DIEGO, CA / ACCESSWIRE / May 9, 2023 / Ensysce Biosciences, Inc. (NASDAQ:ENSC), clinical-stage biotech company applying transformative chemistry to improve prescription drug safety, today announced completion of PF614-MPAR-101, a clinical study examining the Company's first pain medication with overdose protection, PF614-MPAR. The final Part B of the study examined dose escalation of PF614-MPAR from 25 to 200 mg (1 to 8 dose units) and showed that PF614-MPAR successfully reduced opioid delivery when three or more doses are consumed simultaneously.
We believe PF614-MPAR is the first drug which can limit opioid exposure when too many pills are swallowed, protecting against overdose. In our PF614-MPAR-101 study, the data showed that a 25 mg dose of PF614-MPAR, delivered oxycodone as designed for what may be a prescribed dose of one to two capsules. Importantly, when administering three or more capsules simultaneously, the amount of opioid released and absorbed into the circulation diminished as compared to the unprotected PF614, thereby substantially reducing the risk of overdose.
Opioids are used widely for the treatment of severe pain, for example, in patients fighting cancer and for post-operative pain. Opioids are highly effective but carry a significant risk of abuse, addiction and overdose. Overdoses with opioids continue to be a major issue which may occur due to inadvertent over-use, or purposefully when family members find drugs to experiment with in the medicine cabinet.
According to Dr. William Schmidt, Chief Medical Officer of Ensysce Biosciences, "This first-in-human demonstration of MPAR's unique ability to reduce the adverse consequences of excessive opioid consumption is a major step towards Ensysce's goal of making safer prescription drugs. If approved by the FDA, PF614-MPAR could represent a true game-changer for the treatment of severe pain, and could validate our MPAR™ technology for application to a range of other medications."
"This successful outcome brings us closer to the launch of the first opioid with overdose protection," said Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce Biosciences. "PF614-MPAR is potentially a first-in-class agent designed to treat severe pain while not only reducing the ability to abuse for recreational purposes but also to provide protection from overdose. The results showed that our patented technology MPAR™, which ‘switches off' the active drug release, can limit delivery when excess was consumed. Our next step is to clearly define the drug product for all planned dose strengths to optimize effects across our planned dose range. The PF614-MPAR-101 study is particularly important as a proof-of-concept for the base MPAR™ technology which we believe could be used to control delivery of many other drug classes where there may be a narrow therapeutic range. We are excited to explore this further with other therapies as it may help to save many lives in the future."
About Ensysce Biosciences
Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protection (TAAP) and Multi-Pill Abuse Resistance (MPAR™) platforms, the Company is in the process of developing a unique, tamper-resistant treatment option for pain that minimizes the risk of both opioid drug abuse and accidental or intentional overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit www.ensysce.com.
Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter
ENSC Ensysce Biosciences
Have a sizeable position at .65
My thesis is a Director recently bot a boatload on the open mkt in the higher .40s, lol
News this morning did nothing good. Closed tonight at $0.5017 -$0.0478 (-8.699%)
This is by far the most manipulated ticker I've ever encountered. Don't get shook; this isn't sustainable manipulation.
The PR today wasn't the big news- it's the abuse potential results from study 2 that are the big tuna of the moment, expected before end of month.
ENSC Took a stab at .68
Inside buying on open market and..
Trial Report or something coming soon... :)
Some clinical stage bios warrant consideration, when they look legit. I checked. The low PPS is part and parcel of this category
The Trade: Ensysce Biosciences, Inc. (NASDAQ: ENSC) Director Bob G Gower bought a total of 90,287 shares at an average price of $0.49. To acquire these shares, it cost around $44.09 thousand.
What's Happening: Ensysce Biosciences announced critical step in human abuse potential study of PF614 with database lock.
What Ensysce Biosciences Does: Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs.“
appreciated! Minimum just 1$ pps. Revisited in June
have some here....but dont follow, thus, question: Whats the status with NASDAQ listing continuation? (pps too low)
Ensysce Biosciences, Inc. Announces Closing of $3.0 Million Registered Direct Offering Priced at-the-Market Under NASDAQ Rules
I haven't been as excited about a play in quite some time. If this goes off like it could, millionaires will be made.
Thanks Shift. Hopefully by end of March we should be flying with colours
According to their shareholder presentation last week, full results of the final phase 1 abuse potential study (oral dosing) are expected to be announced by the end of this quarter (end of march). This is where recreational users compare how much they enjoy taking the company's drug PF-614 when compared with oxycodone or sugar pill placebo.
(The first abuse potential study in recreational users was already done, and it compared crushed PF-614 with crushed oxy and crushed sugar pill placebo when inhaled through the nose. The results of the first one were terrific.)
Separately, results of part 3 (the final part) of the overdose prevention part is expected early Q3. This is where healthy (non-user) humans take a large overdose of oxycodone or PF-614 while protected by an opioid blocker drug called naltrexone, which prevents its effects. The amount of drug measured in their blood compares how big a dose they would've gotten. The first 2 parts have already demonstrated that when an overdose is taken of PF-614-MPAR (multi-pill abuse resistant), the later pills have no effect. The third part is underway, and like I said the results are expected early Q3.
Those are the two remaining phase 1 studies. Sometime between the two, the one planned phase 2 study will start. That will evaluate the speed of onset of PF-614 to demonstrate that the bioequivalence previously established between PF-614 and oxycodone also means equivalent speed of onset. Only one phase 2 study should be required since they have received FDA fast track designation.
You can find all of this information here: https://www.otcmarkets.com/filing/html?id=16322017&guid=8B2-kpqXejz_dth
When will the phase 1 of finals stage completes?
At This Moment Easy Buying!
If Oxy addiction solved, make millions, it is that simple, drug addiction talked about in media everyday is free advertising if this drug works:
“1:52p ET 1/25/2023 - Dow Jones
Ensysce Biosciences Shares Soar 37% on Final Study Stage Initiation of PF614-MPAR
Ensysce Biosciences Inc. shares soared 37% to 93 cents after the company said it initiated the final stage of its Phase 1 study of PF614-MPAR, the overdose protection version of its lead product, PF614.
The clinical stage biotech company said the selected PF614-MPAR formulation will be evaluated by measuring oxycodone release from increasing dose units delivered to a group of healthy subjects in the final stage of the study.
Ensysce said PF614-MPAR is designed to provide optimal pain relief at prescribed doses, while PF614 is a prodrug of oxycodone designed to protect against prescription drug abuse.
Trading on Wednesday was paused for volatility four times and resumed most recently at 10:09 a.m. EDT. Roughly 62.1 million shares had traded as of 1:34 p.m. EDT, compared with its 65-day average volume of roughly 1.3 million shares.
Shares are down 98% over the last 12 months.”
Be Prepared For The Best!
Be Patient. This Will Be A Big Runner***!